Detalhe da pesquisa
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179323
2.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951974
3.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812679
4.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
5.
Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
Can J Anaesth
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38485835
6.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32905676
7.
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
J Urol
; 209(6): 1112-1119, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951811
8.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131040
9.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 380(13): 1235-1246, 2019 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30763142
10.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Future Oncol
; 18(21): 2585-2597, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35656777
11.
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Future Oncol
; 18(40): 4473-4482, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36753353
12.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med
; 378(15): 1408-1418, 2018 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420164
13.
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Oncologist
; 25(8): 652-660, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32463152
14.
Darolutamide in Metastatic Prostate Cancer. Reply.
N Engl J Med
; 386(24): 2345, 2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35704494
15.
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(10): 1404-1416, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30213449
16.
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Oncologist
; 23(2): 193-202, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29183960
17.
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
J Urol
; 199(2): 459-464, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28867562
18.
Common challenges in the development of prediction models.
Headache
; 63(5): 569-570, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114645
19.
Climate Change and Global Food Systems: Potential Impacts on Food Security and Undernutrition.
Annu Rev Public Health
; 38: 259-277, 2017 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28125383
20.
Accelerating fully phase-encoded MRI near metal using multiband radiofrequency excitation.
Magn Reson Med
; 77(3): 1223-1230, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27052204